Results 41 to 50 of about 480,865 (305)

Association of an Egfr Intron 1 Snp with Never-Smoking Female Lung Adenocarcinoma Patients

open access: yes, 2011
Epidermal growth factor receptor (EGFR) plays an important role in the development and progression of a variety of malignant tumors. To test single nucleotide polymorphisms ( SNPs) and haplotypes of the EGFR in modulating the lung cancer susceptibility ...
JOU, YUH-SHAN;HSIAO, CHIN-FU;CHANG, GEE-CHEN;TSAI, YING-HUANG;SU, WU-CHOU;CHEN, YUH-MIN;HUANG, MING-SHYAN;CHEN, HUI-LING;CHEN, CHIEN- JEN;YANG, PAN-CHYR;HSIUNG, CHAO A.   +1 more
core   +1 more source

Design, synthesis and in vitro biological evaluation of quinazolinone derivatives as EGFR inhibitors for antitumor treatment

open access: yesJournal of Enzyme Inhibition and Medicinal Chemistry, 2020
In this paper, a series of novel 3-methyl-quinazolinone derivatives was designed, synthesised and evaluated for antitumor activity in vitro on wild type epidermal growth factor receptor tyrosine kinase (EGFRwt-TK) and three human cancer cell lines ...
Yi Le   +9 more
doaj   +1 more source

GENETIC POLYMORPHISM OF RETROPERITONEAL MYXOID LIPOSARCOMA

open access: yesСибирский онкологический журнал, 2020
Objective: to detect new molecular genetic markers and therapeutic targets in retroperitoneal myxoid liposarcoma.Material and Methods. DNA samples isolated from tumor tissue and obtained from formalinfixed paraffin-embedded (FFPE) slides were used.
A. Yu. Volkov   +4 more
doaj   +1 more source

Correlation of sonographic parameters with renal function in patients with newly diagnosed chronic kidney disease

open access: yesJournal of Ultrasonography, 2022
To correlate sonographic renal parameters (mean renal cortical thickness, length and volume) with renal functions in patients with newly diagnosed chronic kidney disease.
Garg Aborishi   +3 more
doaj   +1 more source

Nuclear EGFR modulation of DNA repair [PDF]

open access: yes, 2011
Overexpression of the epidermal growth factor receptor (EGFR) is associated with resistance to chemotherapy and radiotherapy. EGFR involvement, in repair of radiation-induced DNA damage, is mediated by association with the catalytic subunit of DNA ...
Liccardi, G.
core  

EGFR-Targeted Nanobody Functionalized Polymeric Micelles Loaded with mTHPC for Selective Photodynamic Therapy

open access: yes, 2020
meta-Tetra­(hydroxyphenyl)­chlorin (mTHPC) is one of the most potent second-generation photosensitizers, clinically used for photodynamic therapy (PDT) of head and neck squamous cell carcinomas.
Javier Sastre Toraño (1685377)   +19 more
core   +1 more source

Pediatric Idiopathic Multicentric Castleman Disease Is Often Severe But Responsive to Siltuximab

open access: yesPediatric Blood &Cancer, EarlyView.
ABSTRACT Background Idiopathic multicentric Castleman disease (iMCD) is a potentially fatal immunologic disorder marked by widespread lymphadenopathy and inflammation. Siltuximab, an interleukin‐6 (IL‐6) inhibitor, is the only FDA‐approved treatment for adult patients with iMCD.
Bridget Austin   +17 more
wiley   +1 more source

Antitumor activity of a novel TLR9 agonist and cooperativity with targeted agents [PDF]

open access: yes, 2008
Novel modified Toll-like receptor 9 (TLR9) agonists, termed immune modulatory oligonucleotides (IMOs), exhibit antitumor activity and are currently investigated in cancer patients. Intriguingly, their mechanisms of action on tumor growth and angiogenesis
Garofalo, Sonia
core   +1 more source

The impact of weekly semaglutide, a glucagon-like peptide-1 agonist, on kidney outcomes in adults with type 2 diabetes mellitus

open access: yesJournal of Family Medicine and Primary Care
Background: Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder associated with kidney complications. This study aims to investigate the effects of weekly subcutaneous semaglutide, a GLP-1 agonist, on kidney outcomes.
Ahmad A Algarni   +2 more
doaj   +1 more source

Blockade of the P2Y2 Receptor Attenuates Alcoholic Liver Inflammation by Targeting the EGFR-ERK1/2 Signaling Pathway

open access: yesDrug Design, Development and Therapy, 2022
Zhen-Ni Liu,1– 3,* Qian-Qian Su,4,* Yu-Hui Wang,1– 3,* Xue Wu,1– 3 Xiong-Wen Lv1– 3 1Inflammation and Immune Mediated Diseases Laboratory of Anhui Province, Anhui Institute of Innovative Drugs, School of Pharmacy, Anhui Medical University ...
Liu ZN, Su QQ, Wang YH, Wu X, Lv XW
doaj  

Home - About - Disclaimer - Privacy